In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Dianthus Therapeutics (DNTH – Research Report), ...

Dianthus Therapeutics, Inc. NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing ...

Dianthus Therapeutics has a 52 week low of $18.34 and a 52 week high of $33.77. The stock has a market cap of $659.78 million, a P/E ratio of -8.92 and a beta of 1.72.

NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...

Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

R Squared Ltd bought a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) during the fourth quarter, according to its most recent disclosure with the SEC.The institutional ...

NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of ...

NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On Friday, TD Cowen initiated coverage on Dianthus Therapeutics (NASDAQ:DNTH), assigning a Buy rating to the biopharmaceutical company's stock. The firm joins a ...